Market Cap: $66.47B
Market Cap: $66.47B
Open
$295.07
Prev. Close
$356.94
High
$296.65
Low
$292.56
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets.
Cencora, Inc. trades on the New York Stock Exchange under the ticker COR, priced in USD.
Cencora, Inc. has a market capitalisation of $66.47B, based on its latest share price.
COR trades at 19.38 times its trailing 12-month earnings.
Over the past 52 weeks COR has traded between $244.82 and $377.54.
Yes. Cencora, Inc.'s dividend yields 0.69% at the current share price, paying out 14% of its earnings.
Profitable, with a net margin of 1.0% over the last 12 months.
The analyst consensus rating for COR is Buy. Analysts' average 12-month price target of $383.57 implies 10% upside.
Robert Mauch is the CEO of Cencora, Inc., which is headquartered in Conshohocken.
Generated automatically from reported financial data. General information only, not financial advice.

Cencora's new partnership in the CAR T-cell therapy space marks a significant move in enhancing access to innovative cancer treatments. The company, known for its focus on specialized healthcare distr…

Cencora, a key player in the pharmaceutical distribution industry, attracts attention as Vanguard Capital Management announces a substantial investment in the company. With a disclosed 7.3% stake repo…

Cencora, a leading company in health and specialty services, is poised for significant growth following its recent acquisition of EyeSouth’s retina business. This strategic move amplifies Cencora's pr…
Cencora Faces Leadership Transition with CFO Retirement Announcement Cencora announces the impending retirement of Chief Financial Officer James Cleary, effective June 30, 2026. Cleary has steered the…